Niche CDI focus Position VENENUM BioDesign as a specialized partner for high-value CDI and T2D programs to leverage their advanced screening platform, proprietary 6 million ECLiPS library, and unique target space for collaboration on translational development.

Partnership model Target mid-to-large pharma and CROs seeking co-development and licensing pathways; emphasize their model of advancing discoveries through partnerships with pharmaceutical companies to bring medicines to patients.

Tech edge Highlight access to ultra-high throughput screening, protein engineering, structural biology, medicinal chemistry, and in vivo models as a differentiator for de-risked early programs and faster progression to lead candidates.

Financial signal Revenue range indicates a growing small-to-mid-size biotech with capability to scale collaborations; use this to position as cost-effective yet capable partner for joint development and milestone-driven deals.

Global partner fit Leverage similarities with peers like Selkirk Pharma to align outreach to comparable segment players and contract developers; emphasize shared focus on innovative small molecules and target-rich discovery programs.